CLINICAL TRIAL: A PHASE 2 STUDY OF AZD6244 IN ADVANCED OR METASTATIC HEPATOCELLU

临床试验：AZD6244 在晚期或转移性肝细胞中的 2 期研究

• 批准号: 7950892
• 负责人: John David Roberts
• 金额: $ 1.4万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7950892
• 关键词: Cell Line; Clinical Research; Clinical Trials; Colon; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Institution; Kidney; Lung; MAP Kinase Activation Pathway; MEKs; Malignant neoplasm of pancreas; Oncogenic; Ovary; Pathway interactions; Phase II Clinical Trials; Primary Neoplasm; Research; Research Personnel; Resources; Sampling; Signal Transduction; Source; United States National Institutes of Health; neoplastic cell

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Studies of primary tumor samples and cell lines have shown constituitive activation or over-activation of the MAP kinase pathways in cancers of the pancreas, colon, lung, ovary and kidney. Therefore agents targeting the RAS/RAF/MEK/EFK pathway might inhibit oncogenic signalling in tumor cells.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 对原发性肿瘤样本和细胞系的研究表明，胰腺癌、结肠癌、肺癌、卵巢癌和肾癌中 MAP 激酶途径存在组成性激活或过度激活。 因此，针对 RAS/RAF/MEK/EFK 通路的药物可能会抑制肿瘤细胞中的致癌信号传导。